Province: NIHB Indication: psoriatic arthritis Medication: etanercept (Enbrel®) Listing Status: Listed—CBC Listing Criteria: For the treatment of moderate to severe PSORIATIC ARTHRITIS with at least two of the following: five or more swollen joints if less than five swollen joints, at least one joint proximal to, or including wrist or ankle more than one joint with erosion on imaging study dactylitis of two or more digits tenosynovitis refractory to oral NSAIDs and steroid injections enthesitis refractory to oral NSAIDs and steroid injections (not required for Achilles tendon) inflammatory spinal symptoms refractory to two NSAIDs (minimum four weeks trial each) and has a BASDAI greater than 4 daily use of corticosteroids use of opioids > 12 hours per day for pain resulting from inflammation Patient is refractory to: NSAIDs and methotrexate weekly parenteral (SC or IM) at 20mg or greater (15mg or greater if patient is > 65 years of age) for more than 8 weeks PLUS a minimum of one of the following: leflunomide: 20mg daily for 10 weeks OR gold: weekly injections for 20 weeks OR cyclosporine: 2-5 mg/kg/day for 12 weeks OR sulfasalazine at least 2g daily for 3 months ® ACE Planning & Consulting Inc.